Published in Lab Invest on January 01, 1992
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep (2010) 1.74
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl (2011) 1.51
Inflammation and benign prostatic hyperplasia. Urol Clin North Am (2008) 1.44
The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine (2008) 1.41
Characterization of prostate cell types by CD cell surface molecules. Am J Pathol (2002) 1.38
Acute bacterial inflammation of the mouse prostate. Prostate (2011) 1.16
Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model. Prostate (2013) 1.06
CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One (2012) 1.03
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate (2010) 1.03
Leukocytic promotion of prostate cellular proliferation. Prostate (2010) 0.98
CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate (2012) 0.97
Role of interleukins, IGF and stem cells in BPH. Differentiation (2011) 0.97
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
Chemokines and BPH/LUTS. Differentiation (2011) 0.93
The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol (2002) 0.91
Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo. Retrovirology (2008) 0.91
Etiopathogenesis of benign prostatic hypeprlasia. Indian J Urol (2009) 0.84
The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med (2011) 0.82
Prostate angiogenesis in development and inflammation. Prostate (2013) 0.81
IL17 Mediates Pelvic Pain in Experimental Autoimmune Prostatitis (EAP). PLoS One (2015) 0.81
Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget (2016) 0.81
Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm (2014) 0.80
Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS). PLoS One (2015) 0.79
Effects of hexanic extract of serenoa repens (permixon(®) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate (2015) 0.79
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One (2013) 0.78
Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol (2014) 0.78
Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia. Urol Clin North Am (2016) 0.77
Defective functional response to membrane stimuli in lymphocytes from patients with benign prostatic hyperplasia. Clin Exp Immunol (1995) 0.76
Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis. Korean J Parasitol (2016) 0.75
CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway. Sci Rep (2017) 0.75
Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochem Med (Zagreb) (2015) 0.75
Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model. PLoS One (2017) 0.75
Molecular pathogenesis of human prostate basal cell hyperplasia. Prostate (2017) 0.75
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol (2000) 2.66
Specificity of the protein kinase activity associated with the hemin-controlled repressor of rabbit reticulocyte. Proc Natl Acad Sci U S A (1976) 2.61
Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int (2003) 2.05
Percutaneous stone manipulation. J Urol (1981) 2.00
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol (1999) 1.86
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol (1998) 1.73
National Bioterrorism Syndromic Surveillance Demonstration Program. MMWR Morb Mortal Wkly Rep (2004) 1.73
Character and spatial distribution of OH/H2O on the surface of the Moon seen by M3 on Chandrayaan-1. Science (2009) 1.70
Is transurethral resection of the prostate still justified? BJU Int (1999) 1.69
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. J Urol (2009) 1.63
High-grade prostate cancer is associated with low serum testosterone levels. Prostate (2001) 1.59
Partial reaction of peptide initiation inhibited by phosphorylation of either initiation factor eIF-2 or 40S ribosomal proteins. Proc Natl Acad Sci U S A (1977) 1.59
Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol (1998) 1.51
The impact of health status on waiting time for major joint arthroplasty. J Arthroplasty (2000) 1.45
Binding specificity of Escherichia coli trigger factor. Proc Natl Acad Sci U S A (2001) 1.45
Low plasma homovanillic acid levels in recently abstinent alcoholic men. Am J Psychiatry (1995) 1.39
The 90-kilodalton peptide of the heme-regulated eIF-2 alpha kinase has sequence similarity with the 90-kilodalton heat shock protein. Biochemistry (1987) 1.38
Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Urology (2000) 1.38
Polyamines are necessary for maximum in vitro synthesis of globin peptides and play a role in chain initiation. Arch Biochem Biophys (1975) 1.37
Distances between 3' ends of ribosomal ribonucleic acids reassembled into Escherichia coli ribosomes. Biochemistry (1980) 1.36
Changes in the redox state and composition of the quinone pool of Escherichia coli during aerobic batch-culture growth. Microbiology (2007) 1.30
Isolation and partial characterization of an Mr 60,000 subunit of a type 2A phosphatase from rabbit reticulocytes. J Biol Chem (1989) 1.29
Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr (1991) 1.28
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Localization of 3' ends of 5S and 23S rRNAs in reconstituted subunits of Escherichia coli ribosomes. Proc Natl Acad Sci U S A (1981) 1.24
Low temperature or GroEL/ES overproduction permits growth of Escherichia coli cells lacking trigger factor and DnaK. FEBS Lett (2004) 1.23
Folding of a nascent peptide on the ribosome. Prog Nucleic Acid Res Mol Biol (2001) 1.23
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol (1997) 1.21
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
Separate pyrimidine-nucleotide pools for messenger-RNA and ribosomal-RNA synthesis in HeLa S3 cells. Eur J Biochem (1976) 1.18
Synergistic effect of nonspecific immunostimulation and antibiotics in experimental peritonitis. Surgery (1987) 1.17
Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure (2006) 1.16
The NH2-terminal sequence of the alpha and gamma subunits of eukaryotic initiation factor 2 and the phosphorylation site for the heme-regulated eIF-2 alpha kinase. J Biol Chem (1986) 1.15
Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13
Possible involvement of the 90-kDa heat shock protein in the regulation of protein synthesis. J Biol Chem (1989) 1.13
Urolithiasis in allograft kidneys. Urology (2002) 1.13
The aging lower urinary tract: a comparative urodynamic study of men and women. Urology (1998) 1.13
Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol (1999) 1.13
Ribosomes and ribosomal RNA as chaperones for folding of proteins. Fold Des (1997) 1.12
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Br J Urol (1994) 1.11
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Automated data acquisition by confocal laser scanning microscopy and image analysis of triple stained immunofluorescent leukocytes in tissue. J Immunol Methods (2000) 1.10
Chaperone-dependent folding and activation of ribosome-bound nascent rhodanese. Analysis by fluorescence. J Mol Biol (1994) 1.10
Overweight, obesity and elevated blood pressure in children and adolescents. Eur J Med Res (2006) 1.09
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol (1997) 1.09
Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol (1998) 1.09
A type 1 phosphoprotein phosphatase active with phosphorylated Mr = 68,000 initiation factor 2 kinase. J Biol Chem (1989) 1.09
Insulin-like growth factors and prostate cancer. World J Urol (2001) 1.09
Partial reaction of peptide initiation inhibited by the reticulocyte hemin-controlled repressor. Biochem Biophys Res Commun (1976) 1.08
Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol (1998) 1.07
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem (1996) 1.06
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. Urology (2001) 1.06
Renaturation of rhodanese by translational elongation factor (EF) Tu. Protein refolding by EF-Tu flexing. J Biol Chem (1997) 1.05
GTP hydrolysis during methionyl-tRNAf binding to 40 S ribosomal subunits and the site of edeine inhibition. J Biol Chem (1978) 1.05
PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology (1999) 1.05
Late sequelae of the management of ureteral calculi with the ureterorenoscope. J Urol (1986) 1.05
Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope (2001) 1.03
Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology (2000) 1.03
Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol (1998) 1.02
Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF beta, and UVB light. J Invest Dermatol (1992) 1.02
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology (1999) 1.00
Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol (1999) 1.00
Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate (2001) 1.00
Transrenal ureteral embolization. Radiology (1979) 0.99
Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer (2001) 0.99
Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate (2001) 0.99
Role of bacteria in the development of kidney stones. Curr Opin Urol (2000) 0.99
Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: experimental and clinical results. Cardiovasc Radiol (1978) 0.98
Co-translational folding. Curr Opin Struct Biol (1999) 0.98
mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res (2000) 0.98
Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol (1994) 0.98
Spontaneous nontraumatic rupture of a contracted kidney with subcapsular and perirenal hematoma in a patient receiving chronic hemodialysis. Urology (1997) 0.98
Etiology of the pulmonary pathophysiology associated with inhalation injury. Resuscitation (1986) 0.98
Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms. Neurourol Urodyn (1999) 0.97
Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol (2004) 0.95
Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology (2003) 0.95
Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol (1999) 0.95
Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol (2000) 0.95
In vitro protein engineering using synthetic tRNA(Ala) with different anticodons. Biochemistry (1993) 0.95
Activation and release of enzymatically inactive, full-length rhodanese that is bound to ribosomes as peptidyl-tRNA. J Biol Chem (1994) 0.94
Fluorescence studies on the interaction of inhibitor 2 and okadaic acid with the catalytic subunit of type 1 phosphoprotein phosphatases. Biochemistry (1991) 0.94
Intracavernous injection of prostaglandin E1 in impotent men. J Urol (1988) 0.94
Modified laparoscopic nephroureterectomy for treatment of upper urinary tract transitional cell cancer is not associated with an increased risk of tumour recurrence. Eur Urol (2003) 0.92
Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance? Eur Urol (2004) 0.92
Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology (2001) 0.92